Amritsar Online

Fabry disease Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Fabry disease Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 31
14:41 2021
Fabry disease Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Fabry Disease – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Fabry disease-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’sFabry disease–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Fabry disease, historical and forecasted epidemiology as well as the Fabry disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  • According to National Organization for Rare Diseases (NORD), It is estimated that type 1 classic Fabry disease affects approximately one in 40,000 males. The type 2 later-onset phenotype is more frequent than the type 1 phenotype by 3-10 fold, and in some populations may occur as frequently as about 1 in 1,500 to 4,000 males.

  •  US estimate for Fabry disease described in the National Institutes of Health Genetics Home Reference states Fabry disease affects an estimated 1 in 40,000 to 60,000 males.

  • In a study by Colon et al, 2017 newborn screening for Fabry disease performed on the Spanish population revealed a prevalence of genetic alterations in GLA of 0.1% in males (0.013% with classic Fabry disease) 

  • In a study by Doheny et al, 2018 prevalence estimates: among 36820 (23954M and 12866F) haemodialysis screenees, 0.21% males and 0.15% females; among 3074 (2031M and 1043F) renal transplant screenees, 0.25% males and no females; among 5491 (4054M and 1437F) cardiac screenees, 0.94% males and 0.90% females; and among 5978 (3904M and 2074F) stroke screenees, 0.13% males and 0.14% females. Among male and female screenees with pathogenic mutations, the type 1 Classic phenotype was predominant (~60%), except more male cardiac patients (75%) had type 2 Later-Onset phenotype.

Key benefits of the report:

1.The Fabry disease market report covers a descriptive overview and comprehensive insight of the Fabry disease epidemiology and Fabry disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Fabry disease market report provides insights into the current and emerging therapies.

3.Fabry disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Fabry disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fabry disease market.

Request for sample pages: https://www.delveinsight.com/sample-request/fabry-disease-market

Fabry disease: Overview

Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.

It is a multi-systemic and life-threatening condition that is one of the most common lysosomal storage diseases after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleovestibular, and cerebrovascular manifestations. The symptoms include Chronic pain, usually a burning or tingling sensation in the hands and feet. The pain sometimes briefly becomes more intense, requiring medication to bring it down to manageable levels. 

The key players involved in the Fabry disease market:

 

  1. Safoni Genzyme

  2. Idorsia Pharmaceuticals

  3. Protalix Biotherapeutics

  4. Sangamo Therapeutics

  5. 4D MolecularTherapeutics

The launch of the emerging therapies is expected to significantly impact the  Fabry disease treatment scenario in the upcoming years:-

Drug covered

  1. Venglustat

  2. Lucerastat

  3. PRX- 102

  4. ST 920

  5. 4D-310

Request a free sample report @https://www.delveinsight.com/sample-request/fabry-disease-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Fabry disease Patient Share (%) Overview at a Glance

5. Fabry disease Market Overview at a Glance

6. Fabry disease Disease Background and Overview

7. Fabry disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry disease 

9. Fabry disease Current Treatment and Medical Practices

10. Unmet Needs

11. Fabry disease Emerging Therapies

12. Fabry disease Market Outlook

13. Country-Wise Fabry disease Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Fabry disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Fabry disease-Pipeline Insights, 2021

Fabry disease-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fabry disease market. A detailed picture of the Fabry disease pipeline landscape is provided, which includes the disease overview and Fabry disease treatment guidelines.

Fabry disease-Epidemiology Forecast to 2030

DelveInsight’s ‘Fabry disease-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Fabry disease{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Fabry Disease-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

“Fabry Disease – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020” report by DelveInsight offers comprehensive insights on marketed and Phase III products for Fabry Disease. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles